Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 11–20 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 11

    Medicine slug
    acamprosate
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    8
    Source count
    8
    Agreement rate
    1
    Recorded readings

    1. 11%

      Numeric value
      11
      Unit
      %
      Source records
      8

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 8 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94ef2a5c-cc2f-4e7f-b159-b2d38188d5b8 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9803db35-2600-4f42-80c1-43216fd1ba3d (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae6e79c0-a307-4888-b647-1b7be4cb9127 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4473326f-79f1-61b2-e063-6294a90a17a3 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43e9ef60-2d85-4394-906b-93042fea099a (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c729939-d2d2-4e61-acbc-4f1646dc38c1 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91769a96-3182-4e38-90c3-b22c1beae398 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of acamprosate calcium after oral administration is about 11%.

  2. Projected row 12

    Medicine slug
    acamprosate
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    8
    Source count
    8
    Agreement rate
    0.875
    Recorded readings

    1. 20 to 33 hours

      Numeric value
      20
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94ef2a5c-cc2f-4e7f-b159-b2d38188d5b8 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20 to 33 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cfe4675-766f-4f1a-b1a8-96bbdacfcfa5 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20 to 33 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9803db35-2600-4f42-80c1-43216fd1ba3d (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20-33 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae6e79c0-a307-4888-b647-1b7be4cb9127 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20 to 33 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43e9ef60-2d85-4394-906b-93042fea099a (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20 to 33 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c729939-d2d2-4e61-acbc-4f1646dc38c1 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20-33 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91769a96-3182-4e38-90c3-b22c1beae398 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20-33 hours.

    2. 20 hours

      Numeric value
      20
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4473326f-79f1-61b2-e063-6294a90a17a3 (opens source in a new tab)

        Acamprosate label

        Version not recorded · Effective date not recorded

        Elimination After oral dosing of 2 x 333 mg of acamprosate calcium, the terminal half-life ranges from approximately 20 hours to 33 hours.

  3. Projected row 13

    Medicine slug
    acarbose
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 16%

      Numeric value
      16
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:656769ee-e292-4950-83df-a38e6b1a9d6e (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose Tablets may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16-34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ba7a072-03b0-41f2-be7a-101145bdef3a (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose Tablets may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16-34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352dd336-d3f9-4ac5-a000-91d3aef7aca3 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8 to 23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16 to 34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29939129-7d09-4c22-bf3e-491a8a97f4c4 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose tablets may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16-34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722ce9eb-8f7b-4651-a287-d53dd7ab3707 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8 to 23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16 to 34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1b627e1-d78d-47dd-93f5-2bf4998466ba (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose tablets may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16-34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:067c0adc-7322-489d-9baa-1d061b37be36 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Acarbose tablets may affect digoxin bioavailability and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max of digoxin by 26% (90% confidence interval: 16-34%) and decreases mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).

  4. Projected row 14

    Medicine slug
    acarbose
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:656769ee-e292-4950-83df-a38e6b1a9d6e (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ba7a072-03b0-41f2-be7a-101145bdef3a (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352dd336-d3f9-4ac5-a000-91d3aef7aca3 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29939129-7d09-4c22-bf3e-491a8a97f4c4 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722ce9eb-8f7b-4651-a287-d53dd7ab3707 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1b627e1-d78d-47dd-93f5-2bf4998466ba (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:067c0adc-7322-489d-9baa-1d061b37be36 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acarbose activity is approximately 2 hours in healthy volunteers.

  5. Projected row 15

    Medicine slug
    acarbose
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:656769ee-e292-4950-83df-a38e6b1a9d6e (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ba7a072-03b0-41f2-be7a-101145bdef3a (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352dd336-d3f9-4ac5-a000-91d3aef7aca3 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14 to 24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29939129-7d09-4c22-bf3e-491a8a97f4c4 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722ce9eb-8f7b-4651-a287-d53dd7ab3707 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14 to 24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1b627e1-d78d-47dd-93f5-2bf4998466ba (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:067c0adc-7322-489d-9baa-1d061b37be36 (opens source in a new tab)

        Acarbose label

        Version not recorded · Effective date not recorded

        Following oral dosing of healthy volunteers with 14 C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour.

  6. Projected row 16

    Medicine slug
    acebutolol
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 40%

      Numeric value
      40
      Unit
      %
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f8c26c-a1e1-4485-a45f-05c82f7a34b5 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48bded12-09c7-47f2-b162-ec970a77f2d8 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f037a079-fde6-3588-e053-2995a90a6621 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2cd5c0-ee16-4bcb-ad92-3755881dbe79 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff68a002-d46d-4f9f-0705-427844ea3655 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa40a564-a579-15c1-e053-6294a90ad8e9 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        It is subject to extensive first-pass hepatic biotransformation, with an absolute bioavailability of approximately 40% for the parent compound.

  7. Projected row 17

    Medicine slug
    acebutolol
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 3 to 4 hours

      Numeric value
      3
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f8c26c-a1e1-4485-a45f-05c82f7a34b5 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48bded12-09c7-47f2-b162-ec970a77f2d8 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f037a079-fde6-3588-e053-2995a90a6621 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2cd5c0-ee16-4bcb-ad92-3755881dbe79 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff68a002-d46d-4f9f-0705-427844ea3655 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa40a564-a579-15c1-e053-6294a90ad8e9 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours.

  8. Projected row 18

    Medicine slug
    acebutolol
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 2.5 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f8c26c-a1e1-4485-a45f-05c82f7a34b5 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48bded12-09c7-47f2-b162-ec970a77f2d8 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f037a079-fde6-3588-e053-2995a90a6621 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2cd5c0-ee16-4bcb-ad92-3755881dbe79 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff68a002-d46d-4f9f-0705-427844ea3655 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa40a564-a579-15c1-e053-6294a90ad8e9 (opens source in a new tab)

        Acebutolol label

        Version not recorded · Effective date not recorded

        The time to reach peak concentration for acebutolol is 2.5 hours and for diacetolol, after oral administration of acebutolol, 3.5 hours.

  9. Projected row 19

    Medicine slug
    acetylcysteine
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    20
    Source count
    13
    Agreement rate
    1
    Recorded readings

    1. 5.6 hours

      Numeric value
      5.6
      Unit
      hours
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8cca4e4c-85a2-d575-e053-2995a90a6599 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        Elimination: After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d305722-e74f-4f48-8d2c-0daa99144749 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d990ef51-ced2-4359-b99b-092334d2dc9b (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        Elimination: After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2324d60b-4f49-4759-a46e-a06bfce7e8aa (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472f158a-5ab9-4308-8e49-1116e6ea3d39 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ae53725-1abb-4122-9c85-f26c2c31566c (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0310d2-4e70-4b94-8d69-cb5999a32b54 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly­-exponential decay manner with a mean terminal half-life (T1/2) of 5.6 hours.The mean clearance (CL) for acetylcysteine was 0.11 liter/hr/kg and renal CL constituted about 30% of the total CL.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c206c659-16ea-444a-8c60-8a3343400ada (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:277963a0-8ab2-4305-a688-28e47e87c584 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8d3ed96-d7ee-43f4-986c-a7d04808711a (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e2e187e-2445-43b1-b66c-b828e2adf022 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T 1/2 ) of 5.6 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6588c28d-0515-4cdf-99d3-c4ad3fd0976c (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T) of 5.6 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f811ddfc-d7c1-4637-ae81-80c38a77cb80 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics After a single intravenous dose of acetylcysteine, the plasma concentration of total acetylcysteine declined in a poly-exponential decay manner with a mean terminal half-life (T1/2) of 5.6 hours.

  10. Projected row 20

    Medicine slug
    acetylcysteine
    Compared field
    proteinBinding
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    20
    Source count
    11
    Agreement rate
    0.909091
    Recorded readings

    1. 66 to 87%

      Numeric value
      66
      Unit
      %
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d305722-e74f-4f48-8d2c-0daa99144749 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2324d60b-4f49-4759-a46e-a06bfce7e8aa (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472f158a-5ab9-4308-8e49-1116e6ea3d39 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ae53725-1abb-4122-9c85-f26c2c31566c (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0310d2-4e70-4b94-8d69-cb5999a32b54 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c206c659-16ea-444a-8c60-8a3343400ada (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:277963a0-8ab2-4305-a688-28e47e87c584 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8d3ed96-d7ee-43f4-986c-a7d04808711a (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e2e187e-2445-43b1-b66c-b828e2adf022 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6588c28d-0515-4cdf-99d3-c4ad3fd0976c (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66 to 87%.

    2. 66%

      Numeric value
      66
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f811ddfc-d7c1-4637-ae81-80c38a77cb80 (opens source in a new tab)

        Acetylcysteine label

        Version not recorded · Effective date not recorded

        The protein binding of acetylcysteine ranges from 66% to 87%.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=10

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy